Oculogica’s New Patent Opens Potential for a CTE Test for Live Subjects
24 juin 2021 09h30 HE
|
Oculogica, Inc.
NEW YORK, June 24, 2021 (GLOBE NEWSWIRE) -- Oculogica, a leader in concussion diagnosis and categorization, with the only FDA-cleared technology that aids in the diagnosis of concussion without the...
Oculogica Adds to IP Portfolio with Patent for Assessment of Impairment Due to Cannabis
25 mai 2021 10h45 HE
|
Oculogica, Inc.
NEW YORK, May 25, 2021 (GLOBE NEWSWIRE) -- Oculogica, a leader in concussion diagnosis and categorization, with the only FDA-cleared technology that aids in the diagnosis of concussion without a...
Oculogica Receives Department of Defense Grant to Develop Wearable Concussion Diagnostic with Pre-eminent Partners
18 mai 2021 09h57 HE
|
Oculogica, Inc.
NEW YORK, May 18, 2021 (GLOBE NEWSWIRE) -- Oculogica, a leader in concussion diagnosis and categorization, with the only FDA-cleared technology that aids in the diagnosis of concussion without a...
Oculogica Announces New Category 3 CPT Code Created by American Medical Association
29 oct. 2019 07h45 HE
|
Oculogica, Inc.
NEW YORK, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Oculogica, Inc., a pioneer in algorithm-based neuro-diagnostics for brain health, announced today that the American Medical Association (AMA) has...
Oculogica Receives FDA Marketing Authorization for EyeBOX®, the First Non-Invasive, Baseline-Free Test for Concussion
03 janv. 2019 07h45 HE
|
Oculogica, Inc.
NEW YORK, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Oculogica, Inc., a pioneer in algorithm-based neuro-diagnostics, announced that the U.S. Food and Drug Administration (FDA) granted their De Novo request...